Buyers Chide Endo's Claim That Class Too Small For Cert. Bid
Direct purchasers who claim they overpaid for pain reliever Opana ER have asked an Illinois federal court to ignore Endo Pharmaceuticals' argument that their proposed class is too small to be...To view the full article, register now.
Already a subscriber? Click here to view full article